• 1
    Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101116.
  • 2
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947952.
  • 3
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:18461850.
  • 4
    Astrom A, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356364.
  • 5
    Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15:163174.
  • 6
    Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ 2000 Type V osteogenesis imperfecta: A new form of brittle bone disease. J Bone Miner Res 15:16501658.
  • 7
    Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R 2002 Osteogenesis imperfecta type VI: A form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:3038.
  • 8
    Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH 2002 Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease. Bone 31:1218.
  • 9
    Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ 1992 Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr 81:953958.
  • 10
    Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD 1990 Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters. J Clin Endocrinol Metab 70:13301333.
  • 11
    Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, Zipf WB 1991 Bone mass in healthy children: Measurement with quantitative DXA. Radiology 179:735738.
  • 12
    Carter DR, Bouxsein ML, Marcus R 1992 New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137145.
  • 13
    Rauch F, Schoenau E 2001 Changes in bone density during childhood and adolescence: An approach based on bone's biological organization. J Bone Miner Res 16:597604.
  • 14
    Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM 1979 Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 32:607629.
  • 15
    Bollen AM, Eyre DR 1994 Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 15:3134.
  • 16
    Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:12931299.
  • 17
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687694.
  • 18
    Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS 1997 Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 249:458468.